* Heplisav protects kidney disease patients in Ph II study
* Shares up 35 pct in after-hours trade
April 14 (Reuters) - Dynavax Technologies Corp (DVAX.O) said a mid-stage study of its experimental hepatitis B vaccine showed that it protected patients with chronic kidney disease from the virus, when measured at week 24.
The vaccine, Heplisav, protected all dialysis and pre-dialysis patients with chronic kidney disease, the company said in a statement.
The study compared two Heplisav regimens -- a single-dose vaccine and a double-dose vaccine -- and enrolled 41 subjects between 40 and 70 years with progressive loss of renal function.
Chronic kidney disease patients undergoing dialysis are at high risk of hepatitis B infection, the company said.
In March 2008, U.S. Food and Drug Administration had put a clinical hold on the vaccine. It is currently in late-stage trials, after the FDA removed the hold last September.
Shares of the company were up 35 percent to $1.95 in trading after the bell. They closed at $1.45 Wednesday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Unnikrishnan Nair)